NCT02992457View on ClinicalTrials.gov

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir

Sofosbuvir 400 mg daily.

DRUG

Ribavirin

Ribavirin 1000-1200 mg daily

DRUG

Pegylated-interferon alfa-2a

Pegylated interferon alfa-2a once weekly for 3 months

DRUG

Simeprevir

Olysio once daily.

DRUG

Daclatasvir

Dakla once daily for three months.

DRUG

Ritaprevir, paritaprevir, ombetasvir

Querevo for three months

DRUG

Sofosbuvir and Ledipasvir

Once daily for three months

DRUG

Salvage therapy

three months in repeated treatment failure

Trial Locations (2)

Unknown

Sherief Abd-Elsalam, Tanta

Tanta university hospital, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT02992457 - Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection | Biotech Hunter | Biotech Hunter